GEORGILIS, Evangelos; ABDELGHANI, Mona; PILLE, Jan; AYDINLIOGLU, Esra; VAN HEST, Jan C.M.; LECOMMANDOUX, Sebastien; GARANGER, Elisabeth

doi:10.1016/j.ijpharm.2020.119537

Métadonnées

Licence d’utilisation du document

GEORGILIS, Evangelos
Laboratoire de Chimie des Polymères Organiques [LCPO]
Team 3 LCPO : Polymer Self-Assembly & Life Sciences

ABDELGHANI, Mona
Eindhoven University of Technology [Eindhoven] [TU/e]

PILLE, Jan
Eindhoven University of Technology [Eindhoven] [TU/e]

Langue

Article de revue

Ce document a été publié dans

International Journal of Pharmaceutics. 2020, vol. 586, p. 119537

Elsevier

Résumé en anglais

Medicine formulations at the nanoscale, referred to as nanomedicines, have managed to overcome key challenges encountered during the development of new medical treatments and entered clinical practice, but considerable improvement in terms of local efficacy and reduced toxicity still need to be achieved. Currently, the fourth-generation of nanomedicines is being developed, employing biocompatible nanocarriers that are targeted, multifunctional, and stimuli-responsive. Proteins and polypeptides can fit the standards of an efficient nanovector because of their biodegradability, intrinsic bioactivity, chemical reactivity, stimuli-responsiveness, and ability to participate in complex supramolecular assemblies. These biomacromolecules can be obtained from natural resources, produced in heterologous hosts, or chemically synthesized, allowing for different designs to access suitable carriers for a variety of drugs. To enhance targeting or therapeutic functionality, additional chemical modifications can be applied. This review demonstrates the potential of polypeptide and protein materials for the design of drug delivery nanocarriers with a special focus on their preclinical evaluation in vitro and in vivo.< Réduire

Mots clés en anglais

Polypeptides

Synthetic proteins

Nanomedecine

Drug delivery

Nanocarriers

Nanoparticles/administration & dosage

URI

https://oskar-bordeaux.fr/handle/20.500.12278/19670

DOI

http://dx.doi.org/10.1016/j.ijpharm.2020.119537

Projet Européen

Nanomedicine: an integrative approach

Project ANR

Développement de polymersomes avec possibilité de suivi par imagerie et activation à distance pour la libération de composés d’intérêt thérapeutique dans des tissus profonds - ANR-14-CE08-0013
Développement de squelettes polypeptidiques recombinants pour la synthèse de glycoconjugués multivalents parfaitement définis - ANR-15-CE07-0002

Origine

Importé de hal

Unités de recherche

Laboratoire de Chimie des Polymères Organiques (LCPO) - UMR 5629